Healthcare

This week, Roche said it extended its tender-offer period for outstanding shares of Spark to Oct. 1 from Sept. 3.

uniQure N.V. announced that the planned enrollment of 56 patients has been achieved in the HOPE-B pivotal trial of etranacogene dezaparvovec, an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B.

A Magnetic Particle Imaging scanner will be installed in The F.M. Kirby Imaging Center at Kennedy Krieger Institute in Baltimore, Maryland.

It is estimated that nearly 5 million people visit the emergency room each year for a suspected concussion. However, about half of all concussions go undetected with current standard-of-care analysis, including CT scans.

Study will evaluate outcomes from integrating oral health care with community health center services

Philadelphia, PA – Oncoceutics, Inc., announced that it has signed an exclusive, world-wide license for US patent #10,239,877, entitled “Pharmacophore for trail induction”, from The Scripps Research Institute, covering the composition of matter of ONC201 as well as other molecules in the imipridone family.

Sandra Horning, Roche’s chief medical officer and head of global product development, will retire from the company at the end of the year, leaving some big shoes to fill.

The FDA approved Rozlytrek for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer. Also, Rozlytrek secured accelerated approval for the treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.

An article published in Experimental Biology and Medicine describes a new class of kinase inhibitors.

There are numerous ongoing projects between healthcare institutions and biopharmaceutical companies that are focusing on deep dives into patients’ genes, hoping to provide insights that can lead to newer, better drugs developed faster. But they’re not without their controversies.